BioCentury | Dec 2, 2020
Distillery Therapeutics

Targeting an mRNA epigenetic reader protein for breast cancer brain metastasis

...of Chicago, Chicago, Ill.email: chuanhe@uchicago.eduCONTACT: Suyun Huang, Virginia Commonwealth University School of Medicine, Richmond, Va.email: suyun.huang@vcuhealth.org Claire Quang University of Chicago Virginia Commonwealth University Cancer Breast...
BioCentury | Nov 19, 2020
Product Development

BMS Foundation, National Medical Fellowships commit $100M to boost trial diversity

...not great success,” he said.Winn, who is also director of the Massey Cancer Center at Virginia Commonwealth University, said...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...Paul B. Fisher, Virginia Commonwealth University School of Medicine, Richmond, Va. email: paul.fisher@vcuhealth.org Claire Quang University of California San Diego Virginia Commonwealth University Friend...
BioCentury | Jan 2, 2020
Clinical News

Durect looks ahead to liver indications after Phase IIa miss in psoriasis

...steatohepatitis with stage 1-3 fibrosis. DUR-928 is the most advanced candidate from Durect’s collaboration with Virginia Commonwealth University...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...Preclinical Founded: 2017 by Matt Wilsey and Carolyn Bertozzi University collaborators: Stanford University, Harvard University, Virginia Commonwealth University...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Infectious disease

...published online Oct. 25, 2018 doi:10.1016/j.chembiol.2018.10.003 CONTACT: Phillip B. Hylemon, Virginia Commonwealth University, Richmond, Va. email: phillip.hylemon@vcuhealth.org Claire Quang Virginia Commonwealth University Clostridium...
BioCentury | Apr 18, 2018
Distillery Therapeutics

Neurology

...published online March 14, 2018 doi:10.1124/jpet.117.245704 CONTACT: Aron Lichtman, Virginia Commonwealth University, Richmond, Va. email: aron.lichtman@vcuhealth.org Chris Lieu Virginia Commonwealth University Monoglyceride...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...low levels of functional hemoglobin in adults, to help treat sickle cell disease and β-thalassemia. Virginia Commonwealth University...
BioCentury | Jun 17, 2017
Product Development

I-SPY adapts

...replicated it quite nicely,” said Charles Geyer, associate director of the clinical trials office at Virginia Commonwealth University...
...M.D. Anderson Cancer Center, Houston, Texas U.S. Food and Drug Administration (FDA), Silver Spring, Md. Virginia Commonwealth University...
BioCentury | May 3, 2017
Distillery Therapeutics

Cancer

...published online April 20, 2017 doi:10.1158/0008-5472.CAN-17-0298 CONTACT: Devanand Sarkar, Virginia Commonwealth University, Richmond, Va. email: devanand.sarkar@vcuhealth.org Hongjiang Li Virginia Commonwealth University...
Items per page:
1 - 10 of 68
BioCentury | Dec 2, 2020
Distillery Therapeutics

Targeting an mRNA epigenetic reader protein for breast cancer brain metastasis

...of Chicago, Chicago, Ill.email: chuanhe@uchicago.eduCONTACT: Suyun Huang, Virginia Commonwealth University School of Medicine, Richmond, Va.email: suyun.huang@vcuhealth.org Claire Quang University of Chicago Virginia Commonwealth University Cancer Breast...
BioCentury | Nov 19, 2020
Product Development

BMS Foundation, National Medical Fellowships commit $100M to boost trial diversity

...not great success,” he said.Winn, who is also director of the Massey Cancer Center at Virginia Commonwealth University, said...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...Paul B. Fisher, Virginia Commonwealth University School of Medicine, Richmond, Va. email: paul.fisher@vcuhealth.org Claire Quang University of California San Diego Virginia Commonwealth University Friend...
BioCentury | Jan 2, 2020
Clinical News

Durect looks ahead to liver indications after Phase IIa miss in psoriasis

...steatohepatitis with stage 1-3 fibrosis. DUR-928 is the most advanced candidate from Durect’s collaboration with Virginia Commonwealth University...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...Preclinical Founded: 2017 by Matt Wilsey and Carolyn Bertozzi University collaborators: Stanford University, Harvard University, Virginia Commonwealth University...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Infectious disease

...published online Oct. 25, 2018 doi:10.1016/j.chembiol.2018.10.003 CONTACT: Phillip B. Hylemon, Virginia Commonwealth University, Richmond, Va. email: phillip.hylemon@vcuhealth.org Claire Quang Virginia Commonwealth University Clostridium...
BioCentury | Apr 18, 2018
Distillery Therapeutics

Neurology

...published online March 14, 2018 doi:10.1124/jpet.117.245704 CONTACT: Aron Lichtman, Virginia Commonwealth University, Richmond, Va. email: aron.lichtman@vcuhealth.org Chris Lieu Virginia Commonwealth University Monoglyceride...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...low levels of functional hemoglobin in adults, to help treat sickle cell disease and β-thalassemia. Virginia Commonwealth University...
BioCentury | Jun 17, 2017
Product Development

I-SPY adapts

...replicated it quite nicely,” said Charles Geyer, associate director of the clinical trials office at Virginia Commonwealth University...
...M.D. Anderson Cancer Center, Houston, Texas U.S. Food and Drug Administration (FDA), Silver Spring, Md. Virginia Commonwealth University...
BioCentury | May 3, 2017
Distillery Therapeutics

Cancer

...published online April 20, 2017 doi:10.1158/0008-5472.CAN-17-0298 CONTACT: Devanand Sarkar, Virginia Commonwealth University, Richmond, Va. email: devanand.sarkar@vcuhealth.org Hongjiang Li Virginia Commonwealth University...
Items per page:
1 - 10 of 68